Advicor is a drug owned by Abbvie Inc. It is protected by 9 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 15, 2018. Details of Advicor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) |
Expired
|
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(7 years ago) |
Expired
|
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(11 years ago) |
Expired
|
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(11 years ago) |
Expired
|
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(11 years ago) |
Expired
|
| US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(11 years ago) |
Expired
|
| US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(11 years ago) |
Expired
|
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(11 years ago) |
Expired
|
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Advicor's patents.
Latest Legal Activities on Advicor's Patents
Given below is the list of recent legal activities going on the following patents of Advicor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 11 Sep, 2015 | US7998506 |
| Correspondence Address Change Critical | 01 Jul, 2013 | US7998506 |
| Email Notification Critical | 07 Oct, 2011 | US7998506 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 Oct, 2011 | US7998506 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Aug, 2011 | US7998506 |
| Recordation of Patent Grant Mailed Critical | 16 Aug, 2011 | US7998506 |
| Email Notification Critical | 28 Jul, 2011 | US7998506 |
| Issue Notification Mailed Critical | 27 Jul, 2011 | US7998506 |
| Application Is Considered Ready for Issue Critical | 13 Jul, 2011 | US7998506 |
| Dispatch to FDC | 13 Jul, 2011 | US7998506 |
US patents provide insights into the exclusivity only within the United States, but Advicor is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Advicor's family patents as well as insights into ongoing legal events on those patents.
Advicor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Advicor's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 15, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Advicor Generics:
There are no approved generic versions for Advicor as of now.
Alternative Brands for Advicor
Advicor which is used for treating hyperlipidemia and hypercholesterolemia by dosing once a day in the evening or at night, with the potential need for flush inhibiting agents like aspirin., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Abbvie |
| |||||||
About Advicor
Advicor is a drug owned by Abbvie Inc. It is used for treating hyperlipidemia and hypercholesterolemia by dosing once a day in the evening or at night, with the potential need for flush inhibiting agents like aspirin. Advicor uses Lovastatin; Niacin as an active ingredient. Advicor was launched by Abbvie in 2001.
Approval Date:
Advicor was approved by FDA for market use on 17 December, 2001.
Active Ingredient:
Advicor uses Lovastatin; Niacin as the active ingredient. Check out other Drugs and Companies using Lovastatin; Niacin ingredient
Treatment:
Advicor is used for treating hyperlipidemia and hypercholesterolemia by dosing once a day in the evening or at night, with the potential need for flush inhibiting agents like aspirin.
Dosage:
Advicor is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG;500MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 20MG;1GM | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 20MG;750MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 40MG;1GM | TABLET, EXTENDED RELEASE | Prescription | ORAL |